Screening and identification of non-inflammatory specific protein markers in Wilms’ tumor tissues

Zhang, Junjie; Guo, Fei; Wang, Lei; Zhao, Wei; Zhou, Da; Yang, Heying; Yu, Jian; Niu, Lili; Yang, Fuquan; Zheng, Shu; Wang, Jiaxiang

doi:10.1016/j.abb.2019.108112

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Coosemans et al [102] proved that 36 patients with endometrial cancers showed overexpression of WT1 in endometrial cells. This research is in conjunction with other reliable cancer reports [103][104][105]. Due to the fact that immunization principles for inducing an immune response are more or less identical in different peptide protocols, WT1 immunotherapy, fortunately, may provide diagnostic tools and prognostic markers for all solid cancers.…”

Section: Wt1mentioning

confidence: 78%

Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects

et al. 2023

View full text Add to dashboard Cite

Breast cancer is considered the second-leading cancer after lung cancer and is the most prevalent cancer among women globally. Currently, cancer immunotherapy via vaccine has gained great attention due to specific and targeted immune cell activity that creates a potent immune response, thus providing long-lasting protection against the disease. Despite peptides being very susceptible to enzymatic degradation and poor immunogenicity, they can be easily customized with selected epitopes to induce a specific immune response and particulate with carriers to improve their delivery and thus overcome their weaknesses. With advances in nanotechnology, the peptide-based vaccine could incorporate other components, thereby modulating the immune system response against breast cancer. Considering that peptide-based vaccines seem to show remarkably promising outcomes against cancer, this review focuses on and provides a specific view of peptide-based vaccines used against breast cancer. Here, we discuss the benefits associated with a peptide-based vaccine, which can be a mainstay in the prevention and recurrence of breast cancer. Additionally, we also report the results of recent trials as well as plausible prospects for nanotechnology against breast cancer.

show abstract

Section: Wt1mentioning

confidence: 78%

Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Although epidemiological studies have not identified clear risk factors for childhood cancer so far, early diagnosis is essential to improve treatment results for childhood cancer P r e p r i n t [10]. Also lack of specific manifestations in the early stage of many tumors usually delays its diagnosis and prevents treatment in the early stage [11]. US screening examinations have been tried several times in the diagnosis of children, mainly in the assessment of the urinary tract [12,13].…”

Section: Discussionmentioning

confidence: 99%

Ultrasound screening for cervical, abdominal and scrotal malignant and benign abnormalities in children

et al. 2021

View full text Add to dashboard Cite

IntroductionUltrasonography plays an important role in evaluation of many diseases in pediatric population. The noninvasiveness of the method allows to its wide use in children. It is a first-line diagnostic test for detecting lymphadenopathy, benign and malignant abnormalities of the thyroid gland, abdominal structures or testes in boys. The Ultrasound Screening Program “No to Cancer in Children” was introduced to detect neoplastic lesions and possible developmental disorders in children with no symptoms to allow early diagnosis.Material and methodsThe children were scanned in special mobile ambulance - Ronald McDonald Care Mobile, equipped with two high-tech ultrasound devices. Ultrasound scans, including cervical, abdominal, pelvical and scrotal ultrasound were performed in population of asymptomatic children. In the years 2006-2019, 67.594 children, 34.892 boys and 32.702 girls aged from 9 months to 6 years were examined.ResultsTotally, 18.544 various abnormalities were detected. In case of the neck they were found in 7542 children, which represent nearly 11.2% of all patients. Changes in abdominal ultrasound were found in 4.496 cases (6.65%). Abnormalities of the male reproductive system were detected in 6.474 boys (18.5%). Twelve tumors were detected.ConclusionsScreening has proved to be very useful for the early identification cancerous as well as precancerous lesions. It is also worth continuing for a reason of effective detection of other childhood anomalies.

show abstract

Screening of serum protein biomarkers in hemorrhagic cerebral infarction by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology

2020

View full text Add to dashboard Cite

Background: Serum samples of patients with hemorrhagic cerebral infarction (HCI), cerebral infarction (CI), and healthy controls (HCs) were used to screen statistically different protein peaks as potential biomarkers and to establish a decision tree classification model. Methods:The serum samples from clinically confirmed patients with HCI and CI from November 2018 to October 2019 were collected, along with those of HCs who visited our hospital during the same period. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) with CM10 ProteinChip was used to analyze the differences in serum protein expression profiles of 30 patients with HCI, 32 patients with CI, and 31 HCs in the training group, and a decision tree classification model was established. At the same time, the blind test group (18 patients with HCI, 21 patients with CI, and 17 HCs) was tested by a blind method.Results: Model 1 was successfully established by software analysis with a mass-to-charge ratio of 3,495.2, 8,941.0, and 15,890.4 as a differential protein peak. The sensitivity, specificity, and accuracy of model 1 in distinguishing HCI from HCs were 86.8%, 87.1%, and 86.9%, respectively. After verification of model 1 by the blind test group, the results showed that the sensitivity, specificity, and accuracy were 88.9%, 94.1%, and 91.4%, respectively. The sensitivity, specificity, and accuracy of model 2 with a mass-to-charge ratio of 2,941.3 as a differential protein peak were 86.7%, 75.0%, and 80.6%, respectively. After verification of model 2 by the blind test group, the results showed that the sensitivity, specificity, and accuracy were 83.3%, 90.4%, and 87.2%, respectively.Conclusions: Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) and CM10 ProteinChip can be used to screen serum protein markers in patients with HCI. Massto-charge ratio of 3,495.2, 8,941.0, 15,890.4, and 2,941.3 may be potential protein biomarkers of HCI and used to distinguish HCI patients from HCs and CI.

show abstract

Screening and identification of non-inflammatory specific protein markers in Wilms’ tumor tissues

Cited by 3 publications

References 30 publications

Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects

Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects

Ultrasound screening for cervical, abdominal and scrotal malignant and benign abnormalities in children

Screening of serum protein biomarkers in hemorrhagic cerebral infarction by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) technology

Contact Info

Product

Resources

About